HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced on April 15, 2026, that it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The offering's final size and terms are subject to market conditions, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. The company intends to use the net proceeds to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities, and support working capital and general corporate purposes.
The announcement comes as HeartBeam seeks to capitalize on its recent FDA clearances. In December 2024, the company received FDA clearance for its 3D ECG technology for arrhythmia assessment, followed by clearance for its 12-lead ECG synthesis software in December 2025. The company's platform technology is designed to be the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
HeartBeam's focus on AI enhancement aligns with broader trends in digital health, where machine learning is increasingly used to improve diagnostic accuracy and patient outcomes. The extended-wear patch and heart attack detection initiatives address critical needs in cardiac care, particularly for patients at risk of acute events. The company holds over 20 issued patents related to its technology, underscoring its commitment to innovation in cardiac health management.
The offering is subject to market conditions, and the company has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC). The preliminary prospectus is available on the SEC's website. HeartBeam cautions that forward-looking statements in the announcement involve risks and uncertainties, including those detailed in its SEC filings. The company undertakes no duty to update these statements unless required by law.
For more details, the full press release is available at https://ibn.fm/pxFOz. Additional updates on HeartBeam can be found in the company's newsroom at https://ibn.fm/BEAT.
